Bootstrap Bio and Manhattan Genomics, biotech firms launched last year to pursue human embryo editing for preventing serious diseases, have closed their doors. The companies cited financial difficulties and internal conflicts as reasons for the shutdowns. The developments highlight challenges in the controversial field of gene-edited babies.
Bootstrap Bio and Manhattan Genomics both launched in 2025 with ambitious plans to edit human embryos, aiming to eliminate serious genetic diseases in newborns. These startups sought to pioneer 'designer babies' through advanced gene-editing techniques, sparking debates over ethics and regulation in biotechnology as first reported by WIRED on April 24, 2026. The companies' rapid demise underscores the hurdles facing such ventures. Less than a year after starting operations, both firms announced their shutdowns due to persistent money issues and internal disagreements among teams. No further details on specific financial figures or conflict resolutions were provided. The closures come amid broader scrutiny of gene-editing startups, with keywords like ethics, genetics, and gene editing central to discussions around these technologies. Industry observers note that funding and regulatory pressures have long plagued similar efforts.